Butterfly Medical’s EU MDR certification: what device marketing learns from a two-market launch
EU MDR: Butterfly Medical’s BPH device just won CE certification while its FDA filing waits. What EU-first launches mean for medical device marketing claims.
Eight of twelve digital scribes may be medical devices. None of the twelve said so.
The TGA found 8 of 12 reviewed AI scribes likely meet the device definition and none declared it. What a medical scribe vendor can claim, and how to check.
AI prescribing: what a health brand can say while Utah and the medical boards write the rules
AI prescribing rules are being drafted by state medical boards. See what Utah’s pilots allow, which claims FDA and Texas police, and how to market safely now.
Pharma digital marketing meets the AI answer: Google opens AI Mode to prescription drug ads
Pharma digital marketing changed on 12 October: Google confirmed branded prescription drug ads in AI Mode and AI Overviews. What to check before you spend.
The NMC just wrote down what medical advertising companies can no longer say
NMC banned guaranteed cures, No.1 claims and fake reviews from 6 October 2026. Here is what medical advertising companies must change, and what stays allowed.
Gender-affirming care clinics face a Medicaid funding cliff. Here is the access map
Gender-affirming care clinics face a federal Medicaid funding cliff on 13 October 2026. Here is what is changing, what remains covered, and how to plan ahead.
Biotech marketing: Biotia’s $9m raise and the proof behind it
Biotia’s 1 October raise paired a 97% headline with a 97.2% study. A biotech marketing read of what evidence-led growth actually asks of the claims you publish.
The ambient scribe claim ladder: five rungs, five kinds of proof
An ambient scribe saving 11,000 hours is not the same claim as fewer burnt-out doctors or agents that act. How to word and evidence each rung of the ladder.
AI medical devices: the claim a regulator can quote back at you
AI medical devices face two new regulatory reads: the FDA’s discussion paper, comments due 19 October, and 44 UK recommendations. Six steps for AI claims.
An FDA untitled letter, a word change and the quiet lesson for GLP-1 advertising
An FDA untitled letter hit Novo’s Wegovy ad, and Novo now says customers, not patients. Five practical rules for telehealth and GLP-1 advertising teams.